GRI Bio (GRI) AI Stock Analysis

• Market Cap: $1.21M
• Dividend Yield: N/A
• Average Volume (3M): 692.08K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.25
• Revenue Growth: N/A
• EPS Growth: 98.55%
• Country: US
• Employees: 3
• Sector: Healthcare
• Sector Strength: 65
• Industry: Biotechnology
• EPS (TTM): -203.36
• Shares Outstanding: 727,358
• 10 Day Avg. Volume: 336,604
• 30 Day Avg. Volume: 692,077
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -0.50
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $10.00
• Price Target Upside: 498.80% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

GRI Bio's overall stock score reflects significant challenges in financial performance, with persistent profitability issues and negative cash flow. The technical analysis indicates a bearish trend, adding to the negative sentiment. Valuation metrics are also concerning, with a negative P/E ratio indicating unprofitability. The absence of earnings call data and corporate events leaves the focus on improving operational efficiency and financial stability as pressing areas for the company.

Positive Factors

Clinical Trial Safety

GRI-0621 is safe and well-tolerated in the first 12 patients evaluated in the study, with no observed hyperlipidemia and normal lipid ranges.

Financial Potential

The current valuation of the company is considered attractive with a high upside, given the potential billion-dollar market opportunities.

Market Opportunity

GRI Bio's focus on regulating NKT cells to treat acute and chronic conditions presents a significant opportunity in the biotech sector.

Negative Factors

Clinical Trial Risks

Despite the potential rewards, there are high risks associated with clinical trials that may impact the company's success.

GRI Bio Business Overview & Revenue Model

Company Description

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

How the Company Makes Money

GRI Bio generates revenue through the development and commercialization of its proprietary therapies. The primary revenue streams include licensing agreements with pharmaceutical companies and potential milestone payments and royalties from successful drug candidates developed using their platform technology. Additionally, GRI Bio may engage in strategic partnerships and collaborations with other biotech firms to co-develop and market new therapies. The company's earnings are significantly influenced by its ability to advance drug candidates through clinical trials and secure regulatory approvals, as well as the establishment of lucrative partnerships with larger pharmaceutical entities.

GRI Bio Financial Statement Overview

Summary

GRI Bio shows improvement in revenue and equity position, yet struggles with profitability and cash flow. High operational costs and significant cash burn threaten financial stability despite a robust equity base.

Income Statement

GRI Bio's income statement shows some improvement in revenue from the previous year, with a TTM (Trailing-Twelve-Months) total revenue of $4.91 million, up from $0 in 2022. However, the company continues to face significant challenges in profitability, as indicated by negative net income and EBIT margins. The EBIT margin for the TTM is -103.5%, and the net profit margin is -167%, highlighting ongoing operational inefficiencies and high costs relative to revenue.

Balance Sheet

The balance sheet reflects a stronger equity position, with stockholders' equity of $56.33 million as of the latest period, a recovery from previous negative equity figures. However, the debt-to-equity ratio is low at 0.002, indicating minimal leverage, which could be a positive factor in reducing financial risk. The equity ratio stands at 98.14%, showcasing a strong equity base relative to total assets, albeit with limited asset growth.

Cash Flow

GRI Bio's cash flow statement shows a negative operating cash flow and free cash flow in the TTM, with free cash flow at -$8.61 million. The operating cash flow to net income ratio is 1.05, suggesting the company is burning cash at a rate close to its net losses. Free cash flow growth remains negative, indicating ongoing challenges in generating cash from operations.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
2.30M	0.00	21.77M	0.00	0.00	100.00K
	Gross Profit
2.30M	-4.00K	21.71M	-206.00K	-73.00K	100.00K
	EBIT
-8.24M	-8.23M	-11.39M	-2.24M	-1.06M	-4.79M
	EBITDA
-8.22M	-8.20M	-10.90M	-2.51M	-9.21M	-4.71M
	Net Income Common Stockholders
-8.21M	-8.21M	-13.04M	-3.54M	-1.51M	-4.82M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
5.03M	5.03M	1.81M	9.00K	90.00K	109.00K
	Total Assets
5.74M	5.74M	2.96M	383.00K	218.00K	955.00K
	Total Debt
119.00K	119.00K	14.00K	673.00K	3.61M	336.00K
	Net Debt
-4.91M	-4.91M	-1.79M	664.00K	3.52M	227.00K
	Total Liabilities
1.71M	1.71M	2.70M	2.01M	4.94M	2.41M
	Stockholders Equity
4.03M	4.03M	259.00K	-1.63M	-4.72M	-1.45M
Cash Flow		Free Cash Flow
-8.61M	-8.61M	-9.00M	-1.09M	-847.00K	-3.71M
	Operating Cash Flow
-8.61M	-8.61M	-9.14M	-1.08M	-847.00K	-3.71M
	Investing Cash Flow
0.00	0.00	-8.00K	-3.00K	-3.84M	-2.00K
	Financing Cash Flow
11.83M	11.83M	10.95M	1.01M	600.00K	-4.00K

GRI Bio Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.67
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GRI, the sentiment is Negative. The current price of 1.67 is below the 20-day moving average (MA) of 1.96, below the 50-day MA of 5.17, and below the 200-day MA of 10.63, indicating a bearish trend. The MACD of -1.13 indicates Negative momentum. The RSI at 31.24 is Neutral, neither overbought nor oversold. The STOCH value of 55.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GRI.

GRI Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$5.31B	3.33	-39.82%	2.92%	17.95%	1.84%
SCPX	47 Neutral	$250.76K	―	-91.23%	―	351.08%	74.79%
GRI	42 Neutral	$1.21M	―	-382.57%	―	―	98.55%
ONCO	33 Underperform	$1.00M	―	-233.77%	―	―	-97.16%
SLRX	30 Underperform	$1.53M	―	-164.02%	―	―	79.57%
PCSA	22 Underperform	$1.16M	―	-354.51%	―	―	56.26%
VINC	15 Underperform	$1.44M	―	-431.29%	―	―	48.17%